Global Cell Therapy Technologies (Consumables, Equipment, Software) Market Forecast to 2023 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 3, 2019--The “Cell Therapy Technologies Market by Product (Consumables, Equipment, Software), Cell Type (Human Stem & Differentiated, Animal), Process Stages (Cell Processing, Distribution, Handling, QC), End User, and Region - Global Forecast to 2023” report has been added to ResearchAndMarkets.com’s offering.
The global cell therapy instruments market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4% during the forecast period.
Factors such as rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are driving the growth of this market. However, the high cost of cell-based research and low success rate are expected to restrain market growth during the forecast period.
Based on the product, the cell therapy instruments market is segmented into consumables, equipment, and systems & software. In 2018, the consumables segment is expected to account for the largest share of the cell therapy instruments market. Factors such as increasing investments by companies to develop advanced products as well as government initiatives for enhancing cell-based research are contributing to the growth of the cell therapy consumables market.
Based on process, the cell therapy instruments market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control. The cell processing segment is expected to account for the largest share of the market in 2018 and is expected to grow at the highest CAGR during the forecasted period. The cell processing stage makes the highest use of cell therapy instruments and media, especially during culture media processing. This is the major factor responsible for the large share and high growth of this segment.
Based on cell type, the cell therapy instruments market is segmented into human cells and animal cells. In 2018, the human cells segment is expected to account for the largest share of the cell therapy instruments market. The rising adoption of human cells over animal cells for cell therapeutics research, technological advancements, and the rising incidence of diseases such as cancer and cardiac abnormalities are the key factors driving the growth of this segment.
Major players in this market include Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific (US).
For more information about this report visit https://www.researchandmarkets.com/research/pz3bdk/global_cell?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190103005449/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/03/2019 10:32 AM/DISC: 01/03/2019 10:32 AM